Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311699 | 0.76 | NPC1 (0.35) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL23124318 | 0.69 | DGAT1 (0.33) | — | |
| SCHEMBL10479182 | 0.63 | KMT2A (0.40) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL31564640 | 0.62 | DGAT1 (0.36) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL30319360 | 0.62 | NPC1 (0.38) | NPC1 | |
| SCHEMBL10479252 | 0.62 | LMNA (0.44) | — | |
| SCHEMBL3308032 | 0.62 | IDO1 (0.36) | — | |
| SCHEMBL17980997 | 0.62 | NPC1 (0.41) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL25697650 | 0.61 | DGAT1 (0.41) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL17362771 | 0.61 | DGAT1 (0.40) | EGFRIGF1RSRCFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | P2RY12, P2RY4, P2RY1 | EGFR 3600/4885IGF1R 1506/4885SRC 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.